← Russell 3000 cross-section

TNDM TANDEM DIABETES CARE INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$1.0bn
Net income TTM
$-63m
Free cash flow
$-27m
Composite score
36.9
Sector rank
#1791

Valuation

P / E
EV / EBITDA
EV / sales
1.6
FCF yield
-1.77%
Earnings yield vs 10-yr
-8.93pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-6.1%
EBITDA margin
-2.7%
ROE
-48.6%
ROIC
-16.5%
Revenue growth
4.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Overall, we anticipate higher revenue in this model over the four-year life of each customer compared to the current medical benefit structure. Reimbursement • In 2026, our primary focus is to continue increasing our sales through the pharmacy benefit with improved scalability of operations, expanded coverage and a change in the reimbursement model. Under this model, in 2026, we began experiencing a decrease in sales and gross profit when pumps are shipped. As pharmacy utilization scales, we expect the decrease in sales from pharmacy pump shipments to be offset by an increase in supply sales and gross profit from both our existing installed base and new customers. …TANDEM DIABETES CARE INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →